Eli Lilly's weight-loss drug could generate billions in sales

Investor's Business Daily March 2, 2024, 12:01 AM UTC

Summary: Eli Lilly's new weight-loss drug could generate over $62 billion in 2030 sales, with a potential increase to $81 billion when factoring in next-generation drugs. Analyst Geoff Meacham raised the stock's price target to 1,000, citing a competitive advantage over rivals. Eli Lilly and Novo Nordisk lead the obesity treatment space, with a projected 7% of U.S. adults using GLP-1 agonist drugs for weight loss by 2030. The stock has a 29% year-to-date increase and a Relative Strength Rating of 95.

Full article

Article metrics
Significance6.0
Scale8.0
Magnitude7.0
Potential8.5
Novelty6.0
Actionability7.5
Immediacy9.0
Positivity8.0
Credibility8.0